In this report, cells were treated with HSV-1-induced EVs before being infected with VSV to evaluate the impact of HSV-1 infection-promoted EVs on a secondary infection, while Christos et al. sought to determine if CD63+ EVs from HSV-1-infected cells could be utilized as a broad antiviral strategy/treatment. This evidence concerns the gene CD63 and infection.